Partners Group's Aroma-Zone Gambit Puts a Fee Debate Under the Microscope
Published on 08/06/2026 at 08:21 | Redaktion boerse-global.de
Talks are said to be at an advanced stage, but nothing is signed yet. Partners Group is circling French natural cosmetics brand Aroma-Zone, with the Swiss private markets firm reportedly prepared to pay around €2.0 billion to prise the business away from investment house Eurazeo. The Financial Times and dpa-AFX first flagged the negotiations, though details on structure and timing remain under wraps.
The timing is anything but incidental. Just days earlier, on July 31, Partners Group and CVC Capital Partners unveiled the sale of their majority stake in Polish retailer ?abka Group to Canada's Alimentation Couche-Tard, with completion slated for the fourth quarter of 2026. A successful Aroma-Zone acquisition would signal that exit proceeds are being recycled straight back into fresh deals — a narrative that cuts both ways for a firm wrestling with questions about earnings quality.
The Core Tension: Fee Income vs. Fundraising Firepower
At the heart of the investor debate sits one metric: the contribution of performance fees to overall revenue. In its first-half 2026 business update, Partners Group conceded that these earnings would land below its stated target corridor of 25 to 40 percent of total revenue, citing delayed exits. That admission, paired with net outflows of $3.8 billion from semi-liquid evergreen funds, prompted UBS to downgrade the stock on July 31 from "Buy" to "Neutral," slashing its price target from 1,175 to 705 Swiss francs.
Yet the fundraising machine shows no signs of sputtering. On July 23, the firm announced the final closing of its "Infrastructure Secondaries" program with commitments exceeding $5.5 billion, more than 70 percent of which came from new clients — evidence that the investor base is broadening. Three days earlier, Partners Group had wrapped up "Direct Infrastructure IV," its fourth direct infrastructure vehicle, at over $15 billion. Combined, total commitments for the first half reached $16 billion, up from $12 billion in the prior-year period.
Should investors sell immediately? Or is it worth buying Partners Group?
The question hanging over the stock is whether this record haul translates into durable profitability or merely inflates assets under management without moving the margin needle.
Portfolio Wins Offer a Counter-Narrative
On the operational front, Partners Group is pointing to tangible value creation within its existing holdings. Its U.S. insurance brokerage subsidiary Foundation Risk Partners lifted EBITDA margin by 120 basis points, with the company crediting an AI-driven transformation program developed alongside portfolio firm Version 1. The announcement, made on Monday, underscores how the firm is seeking to generate returns through operational improvement rather than relying solely on acquisition-driven growth.
The infrastructure segment is delivering the strongest signals. The royalty strategy launched in 2024 — which holds licensing rights to properties including "South Park" — saw assets under management jump 50 percent to $1.5 billion in the first half. For optimists, this operational breadth suggests Partners Group can still access large-scale transactions despite the earnings pressure, and a well-priced Aroma-Zone deal would reinforce that point.
A Share Price Caught Between Recovery and Reality
The stock has been clawing back ground. It closed Wednesday at €777.00, up 6.35 percent over seven days, and the 30-day gain stands at 5.93 percent. But the rebound looks modest against the broader picture: the shares remain 17.79 percent below their 200-day moving average and 26.77 percent off their level at the start of the year. The 52-week high of €1,240.00, set on September 2, 2025, still sits 37.44 percent above the current price.
Partners Group at a turning point? This analysis reveals what investors need to know now.
For bears, the combination of fund outflows and weak performance fees is the defining risk. If the evergreen funds keep bleeding, the fee base erodes structurally — regardless of how many new programs close. UBS's downgrade suggests at least part of the analyst community is weighting that trend more heavily than the fundraising headlines. Should an Aroma-Zone deal prove pricey or margin-dilutive, it would intensify rather than settle the debate over capital discipline. And with the transaction still unconfirmed, a breakdown in talks would deflate the takeover speculation that has been building.
The next test arrives September 1, when Partners Group publishes its detailed half-year report with audited financials. That will reveal how deeply the performance-fee shortfall cuts and whether the record fundraising can offset it. Until then, the market is left weighing a bull case built on infrastructure momentum and operational wins against a bear case anchored in fee erosion and redemption pressure — with the Aroma-Zone negotiations poised to tip the scales either way.
Ad
Partners Group Stock: New Analysis - 6 August
Fresh Partners Group information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
